TOLREMO therapeutics Completes USD 39 Million Series A Financing Round with Strategic Investment from Pierre Fabre Invest — TOLREMO therapeutics: Stopping Non-genetic Cancer Drug Resistance as it Emerges
Summary
TOLREMO therapeutics completed a USD 39 million Series A financing round led by BioMedPartners with participation from Pierre Fabre Invest and existing backers. The company will use the proceeds to start a Phase 1 monotherapy dose-escalation study for its lead candidate, TT125-802. TT125-802 aims to block early, non-genetic cancer drug resistance and support more durable responses to targeted therapies. The financing also brought a new board chair and a new scientific advisory board member into the company.
Funding
Amount
$39.0M
Total raised
Date
September 20, 2023
Announcement date
Investors
Pierre Fabre
Lead investors
Company
tolremo.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected